Articles by Hans Hammers, MD, PhD
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
View the live recording of the "The Uromigos' Definition of Oligometastatic" session from Uromigos Live 2024.
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
The Role of SBRT and Metastasis-Directed Therapy for RCC Treatment, Variant Histology Considerations
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
The panel shared their approach to treatment selection for clear cell kidney cancer.
Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.